Thredd Reports Another Successful Quarter With Fintech Transaction Volumes up and New Issuer Signings
10.10.2024 11:08:00 CEST | Business Wire | Press release
20% YOY organic transaction volume growth and new client signings in APAC and the U.S. 48% increase YOY in Buy Now Pay Later (BNPL) solutions across the UK, Europe, and APAC regions B2B virtual card payments up significantly with APAC clients leading the charge
Thredd, a leading next-generation payments processor, today announced positive third-quarter results with 2024 on track to outperform all prior years, powered by transactions up 20%, key global client wins, programme expansions and growth in distinct payment segments and markets.
According to the company, Thredd signed key new clients in the third quarter including digital banks and saw existing B2B programme expansion to the US. The company also announced the launch of virtual card programmes and a major card programme migration in APAC.
The company said these wins and programme launches follow other partnership extensions earlier in the summer with segment leaders in Buy Now Pay Later (BNPL), B2B payments, disbursements, and specialty travel programmes. Thredd client transaction growth across these sectors is further indication of the ongoing gains across the non-traditional issuer payment space, the company said.
“We are truly proud of Thredd’s performance this year as we have signed marquee name clients in regions across the globe, expanded our network capabilities with the addition of the Discover and Diners Club Networks, and added to the deepest roster of fintech management talent in the industry with the additions of Edwin Poot as CTO and Brian Kieley as Chief Client Officer,” said Jim McCarthy, CEO of Thredd, adding, “These results are a direct result of listening very carefully to our clients and responding to their needs with a commitment to serve. We are focused on bringing card programmes live and letting our clients’ successes be the storyline.”
Gene Lockhart, Thredd’s Board Chairman, added, “We believe 2024 will be our best year yet, and the team is capitalizing on this momentum by investing in an aggressive product and technology roadmap that will keep Thredd at the forefront of modern payments processing. Thredd’s leadership position in virtual cards, tokenization, BNPL, global cross-border remittance, payouts, and embedded finance offerings is only the beginning."
BNPL uptake
The Buy Now Pay Later (BNPL) sector continued to thrive in Q3, with Thredd's clients in the UK, Europe, and APAC witnessing combined transaction volume growth of 48%.
“Fintech innovation is driving substantial growth in BNPL, where we’re seeing strong adoption across multiple regions,” said McCarthy. “These solutions are transforming the financial landscape by offering consumers across the globe convenient, flexible, and transparent alternatives to traditional credit products.”
B2B Payments gaining traction
Virtual card proliferation has fuelled significant gains in B2B payments, particularly in APAC where Thredd reported a 110% increase in B2B card-based transactions owed to client growth in the region.
“Our APAC clients are innovating at pace and their customers are rapidly embracing virtual cards to facilitate B2B payments, especially transactions that cross borders,” added McCarthy. “With our addition of Discover and Diners Club Card along with Visa and MasterCard, there are even more opportunities for our clients to expand.”
Travel payouts on the rise
The travel sector showed a strong resurgence in Q3, with Thredd transactions up 27% YTD compared to 2023, driven by payouts to providers within the online travel agent (OTA) ecosystem. As the global travel industry continues its recovery, efficient and scalable payment solutions remain a critical need for travel businesses, the company said.
“Our most recent data underscores the critical role that fintechs continue to play in the global payments ecosystem, particularly as they bring value to previously underserved consumer and business segments,” McCarthy shared.
About Thredd:
Thredd is the trusted next-gen payments processing partner for innovators looking to modernise their payments offerings worldwide. We process billions of debit, prepaid and credit transactions annually, serving over 100 fintechs, digital banks, and embedded finance providers, from consumer to corporate, across 44 countries.
Thredd’s unique offering is its client-centric approach, combining hands-on support with modern, reliable, and scalable technology. Thredd’s assured solution accelerates the development and delivery of consumer and corporate payments components embedded within digital banks, as well as for expense management, B2B payments, crypto, lending, credit, Buy Now Pay Later (“BNPL”), FX, remittance, and open banking innovators. By partnering with our clients from concept to creation with our easily configurable solutions, we allow these leaders the agility to achieve their core business aspirations.
Thredd has enabled market leaders since 2007 and has a highly reliable platform with 99.99% availability. Thredd’s highly customisable solutions on our API-first platform, surrounded by our in-depth industry expertise, value-added services, global presence, and technical resilience, are designed to scale with ease. Thredd is certified by Visa and Mastercard to process transactions globally and has branded offices in London, Newcastle, Singapore, and Sydney, with remote colleagues based all over the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010075166/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom